Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Commentary: Citation graphs may underestimate neuroscience’s influence on AI
An alternative, albeit less quantitative, way to trace this history is through the people who carried ideas between the fields.
Commentary: Citation graphs may underestimate neuroscience’s influence on AI
An alternative, albeit less quantitative, way to trace this history is through the people who carried ideas between the fields.
Commentary: The rising absolute number of neuro-inspired AI papers represents a substantial footprint
Many of the design choices present in the current generation of artificial-intelligence tools parallel purported properties of the brain.
Commentary: The rising absolute number of neuro-inspired AI papers represents a substantial footprint
Many of the design choices present in the current generation of artificial-intelligence tools parallel purported properties of the brain.
Examining the bridge between neuroscience and AI
A citation analysis reveals that the connection between the two fields is real and gaining momentum. But it’s also narrow and tool-heavy; we need to find ways to widen it.
Examining the bridge between neuroscience and AI
A citation analysis reveals that the connection between the two fields is real and gaining momentum. But it’s also narrow and tool-heavy; we need to find ways to widen it.